Here are three notes:
- Comments for discussion are due by Dec. 3, with a focus on the inclusion of certain bulk substances in compounding exemptions under Section 503A of the FD&C Act.
- The committee will review substances such as AOD-9604 for obesity and Thymosin alpha-1 for various infections.
- The event will include presentations from both FDA staff and public participants, who can join in person or online.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
